
OKYO Pharma has announced positive results from its phase 2 trial of urcosimod (formerly OK-101) in neuropathic corneal pain (NCP), …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

